Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CMRX 12.06.2024

Full Press ReleaseSEC FilingsOur CMRX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Chimerix to Speak Today at The White House Cancer Moonshot Forum
  • 12.30.2024 - Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
  • 12.10.2024 - Regulatory Update Call

Recent Filings

  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.30.2024 - 8-K Current report
  • 12.10.2024 - EX-99.1 EX-99.1

DURHAM, N.C.,Dec. 06, 2024(GLOBE NEWSWIRE) --Chimerix(NASDAQ:CMRX), today announced that onDecember 2, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).

The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.

Chimerixis a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.

CONTACTS:Will O’ConnorStern Investor Relations212-362-1200ir@chimerix.comwill@sternir.com

Primary Logo

Source: Chimerix, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com